|
Goetz, Matthew P; Suman, Vera J; Reid, Joel M et al. (2017) First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol 35:3391-3400
|
|
Pratz, Keith W; Rudek, Michelle A; Gojo, Ivana et al. (2017) A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clin Cancer Res 23:899-907
|
|
Hubbard, Joleen M; Kim, George; Borad, Mitesh J et al. (2016) Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Invest New Drugs 34:96-103
|
|
Deming, Dustin A; Ninan, Jacob; Bailey, Howard H et al. (2014) A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs 32:323-9
|
|
Schelman, William R; Traynor, Anne M; Holen, Kyle D et al. (2013) A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs 31:1539-46
|
|
Schenk, Erin; Hendrickson, Andrea E Wahner; Northfelt, Donald et al. (2013) Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs 31:1251-6
|
|
Kumar, Shaji K; Jett, James; Marks, Randolph et al. (2013) Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs 31:1201-6
|
|
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
|
|
Goetz, Matthew P; McKean, Heidi A; Reid, Joel M et al. (2013) UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs 31:1559-67
|
|
Ezzalfani, Monia; Zohar, Sarah; Qin, Rui et al. (2013) Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. Stat Med 32:2728-46
|
Showing the most recent 10 out of 54 publications
